Skip to content
SPY$715.87down −1.96%
Nasdaq$645.04down −2.19%
Nvidia$145.98down −3.30%
SpaceX$138.43down −3.53%
BTC$61,334.00down −2.16%
Gold$3,540.71down −5.30%
Silver$42.30down −8.22%
Brent oil$92.50up +0.37%
DXY103.72down −0.07%
EUR/USD1.0964down −0.09%
USD/JPY159.30down −0.29%
2Y yield4.76%down −4 bp
5Y yield4.86%down −3 bp
10Y yield5.04%down −3 bp

Search FinPrism

Companies · · 3 min read

Editor: Bohdan S.

Moderna returns to profit and lifts its 2026 sales growth outlook

Moderna beat third-quarter forecasts by a wide margin and now sees 2026 revenue growing 15% to 25%. Newer vaccines and sales abroad did the heavy lifting.

Moderna returns to profit and lifts its 2026 sales growth outlook

The short answer

Moderna said third-quarter revenue rose 29% to $1.31 billion and it earned $162 million, after a loss a year earlier. It raised its 2026 revenue growth forecast to 15% to 25%, from up to 10%. The company credits newer vaccines, international sales and lower costs, suggesting less reliance on its original Covid shot.

What happened

Moderna released its third-quarter 2026 results on Friday, and they came in well ahead of what analysts expected. Revenue climbed 29% to $1.313 billion, according to the company's release, against roughly $885 million forecast by analysts surveyed by LSEG, CNBC reported. Net income was $162 million, or 38 cents a share, compared with a loss of $200 million, or 51 cents a share, a year earlier; Wall Street had expected a loss of $1.25 a share. US sales were $780 million and international sales $533 million. Moderna now sees 2026 revenue growing 15% to 25%, up from a prior range of up to 10%, and cut its research and development spending forecast to about $2.7 billion. Its shares gained roughly 3% before the opening bell.

What it means

For years Moderna's fortunes rose and fell with its first Covid vaccine. This quarter hints at a broader business. Chief executive Stéphane Bancel told CNBC that new products and a wider geographic footprint drove the result. One example is the company's next-generation Covid shot, approved in the US in May 2025. Because vaccine contracts are usually agreed early in the year, that product had only a modest start last year and is now contributing for a full season. Growth in Canada, the UK and Asia also helped, along with deliveries under long-term government agreements.

Costs matter as much as sales here. Moderna has been working to shrink its spending, and the lower research and development forecast shows that effort continuing. On CNBC's Squawk Box, Bancel said the quarter combined stronger sales with lower costs, and that the cost work helped Moderna swing to a profit. Turning a profit while still paying for many experimental programs is a meaningful shift for a company that posted a loss in the same quarter last year. The balance sheet is also stronger: cash and investments reached $8.0 billion after a convertible bond sale that raised about $2.6 billion net, according to the company.

The product lineup keeps widening. Moderna's stand-alone flu vaccine, mFLUSIVA, won US approval in August, though Bancel said its American rollout will be limited in 2026 because of the timing. Health Canada has also authorized that flu shot and a combined flu and Covid vaccine for adults 50 and older. Not everything worked: a norovirus trial missed its early success targets, and the company does not plan another group of participants this season.

The bigger driver of the stock this year has been cancer research. Moderna and Merck reported late-stage data showing their personalized melanoma vaccine, given alongside Merck's Keytruda, cut the risk of the cancer returning or death by 42% versus Keytruda alone. The shares fell after part of that data leaked on social media ahead of a medical conference, which Bancel described as a surprising reaction. Even so, CNBC noted the stock is up more than 700% this year, largely on hopes for that shot.

The bull case

Supporters can point to a clean beat on both sales and profit, a much higher growth forecast and falling costs, all at once. Newer vaccines are only starting to reach patients, the flu shot has a fuller US season ahead, and $8.0 billion of cash gives Moderna room to fund its cancer program. If the melanoma vaccine wins approval, it could open a market far beyond respiratory shots.

The bear case

Skeptics note that Covid remains seasonal and contract-driven, so one strong quarter may not repeat. Much of the lift came from international and government deliveries, which can be lumpy. After a gain of more than 700% this year, a great deal of optimism about the cancer vaccine may already be in the price, and setbacks such as the norovirus trial show that not every program will succeed.

Why it matters

For investors

Moderna's results put vaccine and mRNA biotech stocks in focus, and partner Merck also has a stake in how the joint cancer program develops. A stock that has risen this much this year could react sharply to any further news, good or bad.

The wider context

Moderna is a Nasdaq-100 member, so its swings now flow into many index funds held by ordinary savers. Its turnaround also shows how much biotech shares hinge on a few products, which is why their prices can be so volatile.

Market impact

Asset (ticker)Possible moveTimeframeWhy
Moderna (MRNA) ↑ Up Short term Results beat forecasts and the 2026 growth outlook was raised; shares rose about 3% premarket.

The FinPrism newsroom's view of how these figures could move, as of . It is general news commentary, not a recommendation to buy, sell or hold anything.

Frequently asked questions

What did Moderna report for the third quarter of 2026?

Moderna said revenue rose 29% to $1.313 billion and net income was $162 million, or 38 cents a share. A year earlier it lost $200 million. Analysts surveyed by LSEG had expected about $885 million in revenue and a loss of $1.25 a share, according to CNBC.

Why did Moderna raise its 2026 outlook?

The company now expects 2026 revenue growth of 15% to 25%, up from up to 10%. CEO Stéphane Bancel credited newer vaccines such as its next-generation Covid shot, expansion in Canada, the UK and Asia, and lower costs. Moderna also trimmed its research spending forecast to about $2.7 billion.

Why has Moderna stock risen so much in 2026?

CNBC reported the shares are up more than 700% this year, largely on optimism about the personalized melanoma vaccine Moderna is developing with Merck. Late-stage data showed it cut the risk of recurrence or death by 42% when combined with Keytruda, compared with Keytruda alone.

Sources: Moderna company releases (Stock Titan), CNBC

How this was made: written with AI assistance from the sources listed above, following our editorial standards.

Back to the latest